Today there is an over-representation of black people in the mental health system but in the 1960s Irish people were over-represented. 2 Psychiatrists thought that the prevalence of schizophrenia was high in people from the west of Ireland and invented a new syndrome 'western seaboard psychosis'. 3 Anthropologists descended on the unsuspecting immigrants to ask them if their Catholic faith caused their minds to unbalance and psychiatrists followed to dole out antipsychotics. But then some proper research was done and it showed no excess of schizophrenia in Irish immigrants. 4 The methods of case collection in the early studies were poor and cross-cultural comparisons were not properly thought through. 3 Today Irish people are no more likely to be diagnosed with schizophrenia than anyone else. How did this happen? I would love to say that it was because of the new research or because of government initiatives. The research helped a bit but the main cures for anti-Irish discrimination were that the new immigrants were richer, better educated, better informed and more questioning. They would not be fobbed off with a misdiagnosis. An increasing understanding and appreciation of Irish culture also helped reduce anti-Irish discrimination generally. The most effective cure of all was time. A cynic would add that, nowadays, people have a new batch of immigrants (such as asylum seekers) to discriminate against.
So we need fewer new policy drives and more changes of heart. These will only come from changes in society. Blaming individuals or even the NHS will not help. It is refreshing to read the thoughtful editorial on this subject by Professor McKee and others (October 2004, JRSM 1 ). The interaction of micronutrients, whether administered or in deficiency states, and pharmacotherapy, is a neglected field of study in clinical pharmacology. The logistical problems posed by studies of this nature are considerable, but suitable and willing volunteers should be relatively easy to recruit. What is necessary is the diversion of some of the energy and resources devoted to new drug assessment to research units dedicated to this sort of basic but vital understanding of the everyday use of drugs and dietary factors, including micronutrients. It may not be too fanciful to say that, from such evidence as there is available, there is scope for reduction in drug usage, with avoidance of some adverse events and alternative solutions to treatment and prevention of certain diseases. We had a similar experience in a patient with skin disease. Our patient was a woman of 71 who was taking methotrexate 7.5 mg weekly for psoriasis. A flare of her psoriasis, with erythroderma, necessitated admission to hospital. She was experiencing back pain from osteoporosis, for which her general practitioner had prescribed oral morphine sulphate 20 mg four times daily. She took her methotrexate as usual on Sunday and on Monday morning was found to be in acute renal failure (urea 37 mmol/L, creatinine 384 mmol/L, potassium 6.7 mmol/L, sodium 135 mmol/L). This was felt to be secondary to dehydration since she was drowsy, possibly because of the opioid analgesics and not eating or drinking. She later said she had avoided fluids so as not to need the toilet.
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In addition to intravenous fluids she received three doses of 15 mg folinic acid intravenously and then oral calcium folinate. Despite this, five days after taking methotrexate she became pancytopenic (haemoglobin 8.3 g/dL, white cell count 0.20Â10 9 /L, neutrophils 0.02Â10 9 /L, lymphocytes 0.13Â10 9 /L, platelets 28Â10 9 /L). She was transfused with blood and platelets, and was also given
